<?xml version="1.0" encoding="UTF-8"?>
<!--REG30PARAB V1.0 (01-06-2026)-->
<xbrli:xbrl xmlns:in-capmkt="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt" xmlns:in-capmkt-ent="http://www.sebi.gov.in/xbrl/Regulation_30_Para_B_Of_Part_A_Of_Schedule_III/2026-04-30/in-capmkt/in-capmkt-ent" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-types="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.w3.org/1999/xlink"><link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2026-04-30.xsd"/><xbrli:context id="MainI"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">540596</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="MainD"><xbrli:entity><xbrli:identifier scheme="https://www.sebi.gov.in/in-capmkt/ScripCode">540596</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-06</xbrli:startDate><xbrli:endDate>2026-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I_ExecutionOfAgreement"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">540596</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-06</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIIIAxis">in-capmkt:ExecutionOfAgreementMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="I_PartiesOfTheAgreement1"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">540596</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-06</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:typedMember dimension="in-capmkt:PartiesOfTheAgreementAxis"><in-capmkt:PartiesOfTheAgreementDomain>PartiesOfTheAgreementDomain1</in-capmkt:PartiesOfTheAgreementDomain></xbrldi:typedMember></xbrli:scenario></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="INR"><xbrli:measure>iso4217:INR</xbrli:measure></xbrli:unit><in-capmkt:NSESymbol contextRef="MainI">ERIS</in-capmkt:NSESymbol><in-capmkt:NameOfTheCompany contextRef="MainI">Eris Lifesciences Limited</in-capmkt:NameOfTheCompany><in-capmkt:ScripCode contextRef="MainI">540596</in-capmkt:ScripCode><in-capmkt:MSEISymbol contextRef="MainI">NOTLISTED</in-capmkt:MSEISymbol><in-capmkt:ISIN contextRef="MainI">INE406M01024</in-capmkt:ISIN><in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">Agreements (Sub-para 5-Para B)</in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="I_ExecutionOfAgreement">Execution of agreement</in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">New</in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting contextRef="MainI">false</in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting><in-capmkt:DateOfOccurrenceOfEventOrInformation contextRef="MainI">2026-08-05</in-capmkt:DateOfOccurrenceOfEventOrInformation><in-capmkt:TimeOfOccurrenceOfEventOrInformation contextRef="MainI">22:30:00</in-capmkt:TimeOfOccurrenceOfEventOrInformation><in-capmkt:DateOfReport contextRef="MainI">2026-08-06</in-capmkt:DateOfReport><in-capmkt:TypeOfExecutionOfAgreement contextRef="MainI">Loan agreement</in-capmkt:TypeOfExecutionOfAgreement><in-capmkt:DetailsOfExecutionOfAgreement contextRef="MainI">The Company has today drawn down a working capital loan amounting to ₹64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only) from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.</in-capmkt:DetailsOfExecutionOfAgreement><in-capmkt:WhetherProposedOrExecutedAgreementIsInNormalCourseOfBusiness contextRef="MainI">true</in-capmkt:WhetherProposedOrExecutedAgreementIsInNormalCourseOfBusiness><in-capmkt:NumberOfPartiesToTheAgreement contextRef="MainD" unitRef="pure" decimals="0">1</in-capmkt:NumberOfPartiesToTheAgreement><in-capmkt:NameOfPartiesOrCounterPartiesOfTheAgreement contextRef="I_PartiesOfTheAgreement1">Axis Bank Limited (“Bank/Axis”) and Eris Lifesciences Limited (“Company”)</in-capmkt:NameOfPartiesOrCounterPartiesOfTheAgreement><in-capmkt:NatureOfThePartiesOfTheAgreement contextRef="I_PartiesOfTheAgreement1">Party entering into the agreement</in-capmkt:NatureOfThePartiesOfTheAgreement><in-capmkt:DetailsOfShareholdingInTheEntityWithWhomTheAgreementIsExecuted contextRef="I_PartiesOfTheAgreement1">NIL</in-capmkt:DetailsOfShareholdingInTheEntityWithWhomTheAgreementIsExecuted><in-capmkt:NumberOfSharesOfPartyOfTheAgreement contextRef="I_PartiesOfTheAgreement1" unitRef="shares" decimals="INF">0</in-capmkt:NumberOfSharesOfPartyOfTheAgreement><in-capmkt:PercentageOfShareholdingOfPartyOfTheAgreement contextRef="I_PartiesOfTheAgreement1" unitRef="pure" decimals="INF">0</in-capmkt:PercentageOfShareholdingOfPartyOfTheAgreement><in-capmkt:WhetherThePartiesToTheAgreementAreRelatedToPromoterOrPromoterGroupOrAssociateOrHoldingOrSubsidiaryOrGroupCompaniesOrDirectorOrKMPAndItsRelativesInAnyManner contextRef="I_PartiesOfTheAgreement1">false</in-capmkt:WhetherThePartiesToTheAgreementAreRelatedToPromoterOrPromoterGroupOrAssociateOrHoldingOrSubsidiaryOrGroupCompaniesOrDirectorOrKMPAndItsRelativesInAnyManner><in-capmkt:WhetherTheAgreementWouldFallWithinRelatedPartyTransactions contextRef="MainI">false</in-capmkt:WhetherTheAgreementWouldFallWithinRelatedPartyTransactions><in-capmkt:DetailsOfTheAgreementIsNotDoneAtArmsLength contextRef="MainI">The Transaction is with unrelated parties</in-capmkt:DetailsOfTheAgreementIsNotDoneAtArmsLength><in-capmkt:PurposeOfEnteringIntoTheAgreement contextRef="MainI">The Company has today drawn down a working capital loan amounting to ₹64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only) from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.</in-capmkt:PurposeOfEnteringIntoTheAgreement><in-capmkt:SizeOfAgreement contextRef="MainI">64.40 Crores</in-capmkt:SizeOfAgreement><in-capmkt:SignificantTermsOfTheAgreementInBriefSpecialRightsLikeRightToAppointDirectorsOrFirstRightToShareSubscriptionInCaseOfIssuanceOfSharesOrRightToRestrictAnyChangeInCapitalStructure contextRef="MainI">NA</in-capmkt:SignificantTermsOfTheAgreementInBriefSpecialRightsLikeRightToAppointDirectorsOrFirstRightToShareSubscriptionInCaseOfIssuanceOfSharesOrRightToRestrictAnyChangeInCapitalStructure><in-capmkt:WhetherThereIsAnyIssuanceOrTransferOfSharesToTheParties contextRef="MainI">false</in-capmkt:WhetherThereIsAnyIssuanceOrTransferOfSharesToTheParties><in-capmkt:DetailsOfTheLender contextRef="MainI">Axis Bank Limited</in-capmkt:DetailsOfTheLender><in-capmkt:DetailsOfTheBorrower contextRef="MainI">Eris Lifesciences Limited</in-capmkt:DetailsOfTheBorrower><in-capmkt:NatureOfTheLoan contextRef="MainI">Working Capital Term Loan</in-capmkt:NatureOfTheLoan><in-capmkt:WhetherTheLoanIsGrantedOrTaken contextRef="MainI">Taken</in-capmkt:WhetherTheLoanIsGrantedOrTaken><in-capmkt:AmountOfTheLoanGrantedOrTaken contextRef="MainI" unitRef="INR" decimals="0">644000000</in-capmkt:AmountOfTheLoanGrantedOrTaken><in-capmkt:AmountOfTheOutstandingLoan contextRef="MainI" unitRef="INR" decimals="0">1463700000</in-capmkt:AmountOfTheOutstandingLoan><in-capmkt:DateOfExecutionOfLoanAgreementOrSanctionLetter contextRef="MainI">2026-08-05</in-capmkt:DateOfExecutionOfLoanAgreementOrSanctionLetter><in-capmkt:DetailsOfSecurityProvidedToTheLendersOrByTheBorrowersForLoanOrInCaseOutstandingLoansLentToAPartyOrBorrowedFromAPartyBecomeMaterialOnACumulativeBasis contextRef="MainI">The Bank willl have a second charge on assets (both primary and collateral) already created for its existing working capital credit facilities.</in-capmkt:DetailsOfSecurityProvidedToTheLendersOrByTheBorrowersForLoanOrInCaseOutstandingLoansLentToAPartyOrBorrowedFromAPartyBecomeMaterialOnACumulativeBasis><in-capmkt:DetailsOfNomineeOnTheBoardOfDirectorsOfTheListedEntity contextRef="MainI">NA</in-capmkt:DetailsOfNomineeOnTheBoardOfDirectorsOfTheListedEntity><in-capmkt:PotentialConflictOfInterestArisingOutOfLoanAgreement contextRef="MainI">NA</in-capmkt:PotentialConflictOfInterestArisingOutOfLoanAgreement></xbrli:xbrl>
